Published online Jul 19, 2024. doi: 10.5498/wjp.v14.i7.1062
Revised: May 7, 2024
Accepted: May 30, 2024
Published online: July 19, 2024
Processing time: 94 Days and 18.2 Hours
Chemotherapy for malignant tumors can cause brain changes and cognitive impairment, leading to chemotherapy-induced cognitive impairment (CICI). Current research on CICI has focused on breast cancer and Hodgkin’s lymphoma. Whether patients with non-Hodgkin’s lymphoma (NHL) undergoing chemo
To investigate whether NHL patients undergoing chemotherapy had cognitive impairments.
The study included 100 NHL patients who were required to complete a comprehensive psychological scale including the Brief Psychiatric Examination Scale (MMSE) at two time points: before chemotherapy and within 2 wk of two chemo
The VFT scores for before treatment (BT) and after treatment (AT) groups were 45.20 ± 15.62, and 42.30 ± 17.53, respectively (t -2.16, P < 0.05). The CDT scores were 8 (3.5-9.25) for BT and 7 (2.5-9) for AT groups (Z -2.1, P < 0.05). Retrospective memory scores were 13.5 (9-17) for BT and 15 (13-18) for AT (Z -3.7, P < 0.01). The prospective memory scores were 12.63 ± 3.61 for BT and 14.43 ± 4.32 for AT groups (t -4.97, P < 0.01). The ECog-12 scores were 1.71 (1.25-2.08) for BT and 1.79 (1.42-2.08) for AT groups (Z -2.84, P < 0.01). The SDMT and MMSE values did not show a significant difference between BT and AT groups.
Compared to the AT group, the BT group showed impaired language, memory, and subjective cognition, but objec
Core Tip: The cognitive status of patients with non-Hodgkin’s lymphoma before and after chemotherapy was assessed using various cognitive scales. We observed chemotherapy-related cognitive impairment. Patients with non-Hodgkin’s lymphoma undergoing chemotherapy may experience chemotherapy-related cognitive impairment. The main manifestations were language, memory, and visuospatial dysfunction. Frontal lobe injury was more obvious, but no clear difference was observed in executive function.